My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every-time.
Start Systematic Stock Investing ...in less than a minute.
BSE: 524348 | NSE: AARTIDRUGS | Pharmaceuticals & Drugs | Small Cap
1. Is Aarti Drugs Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Aarti Drugs Ltd is a average quality company.
2. Is Aarti Drugs Ltd undervalued or overvalued?
The key valuation ratios of Aarti Drugs Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Aarti Drugs Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Strong which suggest that the price of Aarti Drugs Ltd is likely to Rise in the short term. However, please check the rating on Quality and Valuation before investing
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'10 | Mar'11 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 12.5% | 9.3% | 18% | 12.8% | 12.6% | 11.6% | 11.5% | 15.8% | 25.9% | 15.7% | - | ||
| Value Creation Index ⓘ | -0.1 | -0.3 | 0.3 | -0.1 | -0.1 | -0.2 | -0.2 | 0.1 | 0.9 | 0.1 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 479 | 501 | 1,097 | 1,140 | 1,195 | 1,244 | 1,561 | 1,806 | 2,155 | 2,489 | 2,716 | ||
| YoY Gr. Rt. % | - | 4.7% | 118.9% | 3.9% | 4.9% | 4.1% | 25.5% | 15.7% | 19.3% | 15.5% | - | ||
| Adj EPS ⓘ | 2.9 | 2.5 | 8 | 7.1 | 8.4 | 8.7 | 9.2 | 14.8 | 29.8 | 22.1 | 18 | ||
| YoY Gr. Rt. % | - | -16.3% | 224.4% | -11.2% | 18.8% | 3.7% | 5.8% | 60.6% | 101.1% | -25.8% | - | ||
| BVPS (₹) ⓘ | 15.1 | 16.8 | 31.8 | 36.9 | 41.9 | 48.3 | 57.6 | 70 | 98 | 111.9 | 128.8 | ||
| Adj Net Profit ⓘ | 28.4 | 23.9 | 77.3 | 68.7 | 80.3 | 82.3 | 87.1 | 138 | 278 | 205 | 166 | ||
| Cash Flow from Ops. ⓘ | 59.1 | 20.6 | 105 | 133 | 175 | 69.8 | 143 | 251 | 155 | 69.6 | - | ||
| Debt/CF from Ops. ⓘ | 3.2 | 13 | 4.3 | 3.6 | 2.7 | 7.8 | 3.5 | 1.5 | 2.2 | 7.7 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 20.1% | 15.8% | 16.8% | 15.5% | ||||||||
| Adj EPS ⓘ | 25.2% | 21.3% | 33.8% | -25.8% | ||||||||
| BVPS ⓘ | 24.9 | 21.7 | 24.8 | 14.2 | ||||||||
| Share Price | 32.8% | 29.3% | 22.6% | 6.9% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'10 | Mar'11 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 21.1 | 15.4 | 32.8 | 20.7 | 21.2 | 19.2 | 17.4 | 23.1 | 35.5 | 21 | 14.9 | |
| Op. Profit Mgn % ⓘ | 17.3 | 13.8 | 15.7 | 15.8 | 15.9 | 16.2 | 13.5 | 14.7 | 20.4 | 13.4 | 11.3 | |
| Net Profit Mgn % ⓘ | 6 | 4.7 | 7 | 6 | 6.7 | 6.6 | 5.6 | 7.7 | 12.9 | 8.2 | 6.1 | |
| Debt to Equity ⓘ | 1.3 | 1.6 | 1.5 | 1.4 | 1.2 | 1.2 | 0.9 | 0.6 | 0.4 | 0.5 | 0.2 | |
| Working Cap Days ⓘ | 141 | 156 | 121 | 162 | 162 | 191 | 178 | 170 | 165 | 180 | 181 | |
| Cash Conv. Cycle ⓘ | 81 | 90 | 61 | 81 | 76 | 94 | 91 | 89 | 82 | 99 | 68 | |
Sales growth is growing at healthy rate in last 3 years 16.82%
Net Profit is growing at healthy rate in last 3 years 33.81%
Return on Equity has declined versus last 3 years average to 14.90%
Sales growth is not so good in last 4 quarters at 9.35%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 16.5 | 18 |
| TTM Sales (₹ Cr.) | 2,498 | 2,716 |
| BVPS (₹.) ⓘ | 120.3 | 128.8 |
| Reserves (₹ Cr.) ⓘ | 1,022 | 1,100 |
| P/BV ⓘ | 3.79 | 3.54 |
| PE ⓘ | 27.64 | 25.40 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 310.80 / 511.65 |
| All Time Low / High (₹) | 0.57 / 1025.00 |
| Market Cap (₹ Cr.) | 4,224 |
| Equity (₹ Cr.) | 92.6 |
| Face Value (₹) | 10 |
| Industry PE ⓘ | 37.9 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Aarti Drugs Ltd. was established in the year 1984 and forms part of $900 Million Aarti Group of Industries with robust R&D Division at Tarapur, Maharashtra Industrial Development Corporation (MIDC) in close vicinity to manufacturing locations.
Over the years, the Company has been able to carve a niche for itself and is looking forward to expand the volumes. With the government initiative to encourage private health insurance schemes, consumer spending on medicines is expected to increase, which will spur growth in the generic sector in the domestic market.
The manufacturing-units of Aarti Drugs Ltd. are GMP certified. The Company is also in the process of acquiring an ISO 9002 compliance for all its units and one of the units has already been approved.
The Company aims at becoming the first choice of this expanding market through better products, ensuring quality and timely delivery.
Business area of the company
The company is engaged in the manufacturing of Active Pharmaceutical Ingredients (APIs), Pharma Intermediates, Specialty Chemicals and also produces Formulations with its wholly-owned subsidiary - Pinnacle Life Science Private Limited.
Products under APIs includes Ciprofloxacin Hydrochloride, Metronidazole, Metformin HCL, Ketoconazole, Ofloxacin etc. whereas Specialty Chemicals includes Benzene Sulphonyl Chloride, Methyl Nicotinate etc.
Awards and accolades
Milestones
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Download APP
